QUOTE AND NEWS
FiercePharma  Jun 30 
Are expensive cancer drugs a contemporary version of the emperor's new clothes? The Journal of the National Cancer Institute says they just might be. After analyzing data from existing studies, researchers found that some of the costliest drugs in...
Bloomberg  Jun 29 
Eli Lilly & Co.’s tumor-fighter Erbitux doesn’t prolong lung cancer patients’ lives enough to justify its $80,000 cost, U.S. scientists said in commentary published today.
PR News Wire  Jun 22 
INDIANAPOLIS, June 22 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the third quarter of 2009 of $0.49 a share on outstanding common stock. This is the same dividend as was paid in
Stocks and Blogs  Jun 19 
This post was submitted by Laura Stevens of the Rosen Group. Dads, you're probably expecting a tie or a set of power tools this Father's Day. If you have enough of those already (or even if you don't), Kiplinger.com has a gift you'll really...
Dividend Growth Investor  Jun 19 
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of pharmaceutical products in the United States, Puerto Rico, and internationally. The company offers neuroscience products, endocrine products, oncology products,...
Bloomberg  Jun 13 
A unit of CVS Caremark Corp. used its access to doctors who treat the mentally ill to market Eli Lilly & Co.’s Zyprexa antipsychotic while it was under contract to bargain with the drugmaker on behalf of health insurers, internal Lilly files...
Bloomberg  Jun 12 
Eli Lilly & Co. officials wrote medical journal studies about the antipsychotic Zyprexa and then asked doctors to put their names on the articles, a practice called “ghostwriting,” according to unsealed company files.
Bloomberg  Jun 11 
Eli Lilly & Co. officials wrote medical journal studies about the antipsychotic Zyprexa and then asked doctors to put their names on the articles, a practice called “ghostwriting,” according to unsealed company files.
MarketWatch  Jun 11 
An advisory panel of the Food and Drug Administration recommended late Wednesday that two leading antipsychotic medications, AstraZeneca PLC's Seroquel and Eli Lilly & Co.s' Zyprexa be approved for use in teenagers and certain children suffering...
FiercePharma  Jun 10 
Eli Lilly doesn't appreciate the West Virginia attorney general's broad application of that state's Consumer Credit and Protection Act. The drugmaker contends that AG Darrell McGraw has no right to sue for civil penalties under that law--a...
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
BULLS: REASONS TO BUY

 
87% agree
 
Zyprexa incredibly profitable

 
100% agree
 
Strong dollar spurs quarterly profit

BEARS: REASONS TO SELL

 
16% agree
 
Zyprexa will lose patent protection in 2011

 
36% agree
 
Zyprexa causes Diabetes

 
LLY AT A GLANCE
 
 
 
 
 
 
 
 
Please install Flash Player to view this chart.
     Table of Contents      
Intro and Overview
     Introduction
     Business Overview
Trends and Forces
      Corporate Overview (cont.)
      Key Trends and Forces
Competition

Eli Lilly and Company (NYSE: LLY) is the seventh largest pharmaceutical company with total sales of $20 billion, of which more than a quarter came from Zyprexa, a schizophrenia and bipolar disorder drug (see Antipsychotic Drug Market).[1][2] Although the patent for Zyprexa will expire in 2011, Eli Lilly has one of the youngest product portfolios in the industry -- the company has $6.64 dollars coming from new products (those launched within the last five years) for every dollar lost from patent-expiring ones, compared to an industry average of only 77 cents.[3]

Lilly's most promising pipeline products are Effient (prasugrel), a blood-thinner, and Byetta LAR, a long-acting-release version of the diabetes drug Byetta. Compared to Sanofi-Aventis and Bristol-Myers Squibb's Plavix, Effient is more effective at reducing heart attacks but also increases the risk of major bleeding, but for a net benefit.[4] Effient is under priority review by the FDA.[4] Byetta's biggest advantage over competitors is that it is just as effective but causes weight loss instead of gain, and there are indications that the long-acting version may be even more effective.[5]

2008 sales grew by 9.4 percent to $20.4 billion, and was mainly driven by a 28% growth in the depression and pain-management drug Cymbalta and 18% growth in Humalog.[2]

[edit] Corporate Overview

[edit] Major Products

Eli Lilly's top eight products have each generated net sales of more than $1 billion for 2008.[2]

Eli Lilly 2007 product sales
Eli Lilly 2007 product sales[2]
  • Zyprexa (23% of 2008 sales), Eli Lilly's best-selling product, is in the antipsychotic drug market for the treatment of schizophrenia, bipolar disorder, and other psychological disorders. It has also been used off-label for depression and dementia.[6] A 2005 study showed that Zyprexa was the most effective of its class, but causes significant weight gain -- 30 percent of patients gained more than 22 pounds after a year on the drug -- which leads to an increased risk for diabetes.[7][6] Since 2005, Eli Lilly has spent $1.61 billion to settle 31,200 lawsuits from patients who claimed that Zyprexa caused diabetes or other illnesses.[8] The patent for the drug expires in 2011.[9]
  • Cymbalta (13% of 2008 sales) is a treatment for depression, anxiety, and pain management for diabetics. Sales of the drug grew 60% in 2007 to $2.1 billion due to expansions into new indications, making it Lilly's fastest growing and second largest product. The product's patent expires in 2013. [2]
  • Humalog (8.5% of 2008 sales) is an insulin analog used for managing diabetes.
  • Gemzar (8.4% of 2008 sales) is a chemotherapy drug for lung cancer, pancreatic cancer, and breast cancer. Gemzar mimics a DNA building block, preventing DNA replication and tumor growth.[10] Like many other chemotherapy drugs, this also stops the division of healthy cells, leading to severe side effects.
  • Cialis (7.1% of 2008 sales) is the newest and longest-lasting erectile dysfunction drug on the market.
  • Alimta (5.7% of 2008 sales) is a lung and chest cancer drug.
  • Evista (5.3% of 2008 sales) is an osteoporosis drug only approved for postmenopausal women.
  • Humulin (5.3% of 2008 sales) is another insulin analog used for managing diabetes.

Lilly's animal health division operates independently of its main pharmaceutical business and had sales of $1.09 billion in 2007.[2] (Read More about Eli Lilly's key trends and forces...)

Introduction and Overview | Trends and Forces | Competition




[edit] References

  1. Fortune 500 2009: Industry: Pharmaceuticals.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 LLY 2008 10-k pg. 21  
  3. Tough Projections for Big Pharmas: Drug Revenues Don't Look Promising.
  4. 4.0 4.1 Lilly's Prasugrel Is Granted FDA Priority Review.
  5. Wikipedia:Byetta
  6. 6.0 6.1 Wikipedia:Zyprexa
  7. Cowen and Company. Therapeutic Categories Outlook. March 2008.
  8. LLY 2007 10-k pg. 19  
  9. LLY 2007 10-k pg. 13  
  10. Wikipedia:Gemzar
 
Worried about pump and dump?
We review changes
for stock spam
Want to make Wikinvest better?
We need your help,
contribute today
Do you write software?
We are recruiting
the best engineers
Like Wikinvest?
Spread the word —
Tell your friends!
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki